ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Sitagliptin/metformin 50 mg/1000 mg extended release tablet

Its studies are led by Dexa Medica Group.

Furthest: no phase, since Nov 9, 20261 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dexa Medica Group10 open or runningno phasesince Nov 9, 2026Nov 9, 2026none ahead

Also a collaborator on its studies: PT Equilab International.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2026First study: no phase study in Healthy VolunteersFirst studyNCT07937436 · 30 enrolled · Indonesia

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07937436Healthy Volunteers · Indonesia–CompletedAug 9, 202330

How it is read

Names in the registry

  • “Sitagliptin/metformin 50 mg/1000 mg extended release tablet”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 17, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.